[[Image:Arterial pressure diagram.png|thumb|right|500px|A diagram explaining factors affecting [[arterial pressure]]]]
The '''pathophysiology of hypertension''' is an area of active research, attempting to explain causes of [[hypertension]], which is a chronic disease characterized by elevation of [[blood pressure]]. Hypertension can be classified as either [[Essential hypertension|essential]] or [[secondary hypertension|secondary]]. [[Essential hypertension]] indicates that no specific medical cause can be found to explain a patient's condition. About 90-95% of hypertension is essential hypertension.<ref name="pmid10645931">{{cite journal |author=Carretero OA, Oparil S |title=Essential hypertension. Part I: definition and etiology |journal=[[Circulation (journal)|Circulation]] |volume=101 |issue=3 |pages=329–35 |year=2000 |month=January |pmid=10645931 |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=10645931 |accessdate=2009-06-05 |doi=10.1161/01.CIR.101.3.329}}</ref><ref name="pmid14597461">{{cite journal |author=Oparil S, Zaman MA, Calhoun DA |title=Pathogenesis of hypertension |journal=[[Ann. Intern. Med.]] |volume=139 |issue=9 |pages=761–76 |year=2003 |month=November |pmid=14597461}}</ref><ref name="isbn0-7216-0240-1">{{cite book |author=Hall, John E.; Guyton, Arthur C. |title=Textbook of medical physiology |publisher=Elsevier Saunders |location=St. Louis, Mo |year=2006 |pages=228 |quote= |isbn=0-7216-0240-1 }}</ref><ref name="urlHypertension: eMedicine Nephrology">{{cite web |url=http://emedicine.medscape.com/article/241381-overview |title=Hypertension: eMedicine Nephrology |accessdate=2009-06-05 }}</ref> [[Secondary hypertension]] indicates that the high blood pressure is a result of another underlying condition, such as [[kidney disease]] or [[tumours]] ([[adrenal adenoma]] or [[pheochromocytoma]]). Persistent hypertension is one of the risk factors for [[stroke]]s, [[myocardial infarction|heart attacks]], [[heart failure]] and arterial [[aneurysm]], and is a leading cause of [[chronic renal failure]].<ref name="pmid19498342">{{cite journal |author=Pierdomenico SD, Di Nicola M, Esposito AL, ''et al.'' |title=Prognostic Value of Different Indices of Blood Pressure Variability in Hypertensive Patients |journal=[[American Journal of Hypertension]] |year=2009 |month=June |pmid=19498342 |doi=10.1038/ajh.2009.103 |volume=22 |issue=8 |pages=842–7}}</ref>

Most mechanisms leading to [[secondary hypertension]] are well understood. The [[pathophysiology]] of [[essential hypertension]] remains an area of active research, with many theories and different links to many [[Essential_hypertension#Risk_factors|risk factors]]. 

[[Cardiac output]] and [[Total peripheral resistance|peripheral resistance]] are the two determinants of [[arterial pressure]].<ref name=KlabundeMAP2007>{{cite web|url=http://www.cvphysiology.com/Blood%20Pressure/BP006.htm |title=Cardiovascular Physiology Concepts - Mean Arterial Pressure |accessdate=2008-09-29 |last=Klabunde |first=Richard E. |year=2007 }}</ref> Cardiac output is determined by [[stroke volume]] and [[heart rate]]; stroke volume is related to [[Contractility|myocardial contractility]] and to the size of the [[Blood vessel|vascular compartment]]. Peripheral resistance is determined by functional and anatomic changes in small [[arteries]] and [[arterioles]].

==Genetics==
Evidence for [[Genetics|genetic]] influence on blood pressure comes from various sources.<ref name="pmid10373210">{{cite journal |author=Corvol P, Persu A, Gimenez-Roqueplo AP, Jeunemaitre X |title=Seven lessons from two candidate genes in human essential hypertension: angiotensinogen and epithelial sodium channel |journal=[[Hypertension]] |volume=33 |issue=6 |pages=1324–31 |year=1999 |month=June |pmid=10373210 |doi= |url=http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=10373210 |accessdate=2009-06-08}}</ref> There is greater similarity in [[blood pressure]] within families than between families, which indicates a form of [[inheritance]].<ref name="pmid">{{cite journal |author=Feinleib M, Garrison RJ, Fabsitz R, ''et al.'' |title=The NHLBI twin study of cardiovascular disease risk factors: methodology and summary of results |journal=[[American Journal of Epidemiology]] |volume=106 |issue=4 |pages=284–5 |year=1977 |month=October |pmid= 562066|doi= |url=http://aje.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=562066|accessdate=2009-06-08}}</ref> And it was proved that this finding wasn't due to shared environmental factors.<ref name="pmid974967">{{cite journal |author=Biron P, Mongeau JG, Bertrand D |title=Familial aggregation of blood pressure in 558 adopted children |journal=[[Canadian Medical Association Journal]] |volume=115 |issue=8 |pages=773–4 |year=1976 |month=October |pmid=974967 |pmc=1878814 }}</ref> Single gene mutations are proved to cause [[Mendelian]] forms of [[hypertension|high]] and [[hypotension|low blood pressure]].<ref name="pmid11239411">{{cite journal |author=Lifton RP, Gharavi AG, Geller DS |title=Molecular mechanisms of human hypertension |journal=[[Cell (journal)|Cell]] |volume=104 |issue=4 |pages=545–56 |year=2001 |month=February |pmid=11239411 |doi= 10.1016/S0092-8674(01)00241-0|url=http://linkinghub.elsevier.com/retrieve/pii/S0092-8674(01)00241-0|accessdate=2009-06-08}}</ref> almost 10 genes have been identified to cause these forms of [[hypertension]].<ref name="pmid11239411"/><ref name="pmid11498583">{{cite journal |author=Wilson FH, Disse-Nicodème S, Choate KA, ''et al.'' |title=Human hypertension caused by mutations in WNK kinases |journal=[[Science (journal)|Science]] |volume=293 |issue=5532 |pages=1107–12 |year=2001 |month=August |pmid=11498583 |doi=10.1126/science.1062844 |url=http://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=11498583|accessdate=2009-06-08}}</ref> These mutations affect blood pressure by altering [[Renal_reabsorption#Reabsorption|renal salt handling]].<ref name="pmid2063193">{{cite journal |doi=10.1126/science.2063193 |author=Guyton AC |title=Blood pressure control--special role of the kidneys and body fluids |journal=[[Science (journal)|Science]] |volume=252 |issue=5014 |pages=1813–6 |year=1991 |month=June |pmid=2063193 |url=http://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=2063193|accessdate=2009-06-08}}</ref> Recently and with the aid of newly developed [[genetic analysis]] [[Scientific technique|techniques]] [[researchers]] found [[statistically significant]] linkage of blood pressure to several [[chromosome|chromosomal regions]], including regions linked to familial combined [[hyperlipidemia]].<ref name="pmid10859286">{{cite journal |author=Hsueh WC, Mitchell BD, Schneider JL, ''et al.'' |title=QTL influencing blood pressure maps to the region of PPH1 on chromosome 2q31-34 in Old Order Amish |journal=[[Circulation (journal)|Circulation]] |volume=101 |issue=24 |pages=2810–6 |year=2000 |month=June |pmid=10859286 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=10859286|accessdate=2009-06-08}}</ref><ref name="pmid11040222">{{cite journal |author=Levy D, DeStefano AL, Larson MG, ''et al.'' |title=Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study |journal=[[Hypertension]] |volume=36 |issue=4 |pages=477–83 |year=2000 |month=October |pmid=11040222 |doi= |url=http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=11040222|accessdate=2009-06-08}}</ref><ref name="pmid12052839">{{cite journal |author=Kristjansson K, Manolescu A, Kristinsson A, ''et al.'' |title=Linkage of essential hypertension to chromosome 18q |journal=[[Hypertension]] |volume=39 |issue=6 |pages=1044–9 |year=2002 |month=June |pmid=12052839 |doi= 10.1161/01.HYP.0000018580.24644.18|url=http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=12052839|accessdate=2009-06-08}}</ref><ref name="pmid12105129">{{cite journal |author=Hunt SC, Ellison RC, Atwood LD, Pankow JS, Province MA, Leppert MF |title=Genome scans for blood pressure and hypertension: the National Heart, Lung, and Blood Institute Family Heart Study |journal=[[Hypertension]] |volume=40 |issue=1 |pages=1–6 |year=2002 |month=July |pmid=12105129 |doi= 10.1161/01.HYP.0000022660.28915.B1|url=http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=12105129|accessdate=2009-06-08}}</ref><ref name="pmid2013927">{{cite journal |author=Selby JV, Newman B, Quiroga J, Christian JC, Austin MA, Fabsitz RR |title=Concordance for dyslipidemic hypertension in male twins |journal=[[JAMA : the Journal of the American Medical Association]] |volume=265 |issue=16 |pages=2079–84 |year=1991 |month=April |pmid=2013927 |doi= 10.1001/jama.265.16.2079|url= }}</ref> These findings suggest that there are many [[Locus (genetics)|genetic loci]], each with small effects on blood pressure in the general population. Overall, however, identifiable single-gene causes of hypertension are uncommon, consistent with a multifactorial cause of essential hypertension.<ref name="pmid14597461">{{cite journal |author=Oparil S, Zaman MA, Calhoun DA |title=Pathogenesis of hypertension |journal=[[Annals of Internal Medicine]] |volume=139 |issue=9 |pages=761–76 |year=2003 |month=November |pmid=14597461 |doi= |url= }}</ref><ref name="pmid10373210">{{cite journal |author=Corvol P, Persu A, Gimenez-Roqueplo AP, Jeunemaitre X |title=Seven lessons from two candidate genes in human essential hypertension: angiotensinogen and epithelial sodium channel |journal=[[Hypertension]] |volume=33 |issue=6 |pages=1324–31 |year=1999 |month=June |pmid=10373210 |doi= |url=http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=10373210|accessdate=2009-06-08}}</ref><ref name="pmid10024331">{{cite journal |author=Niu T, Yang J, Wang B, ''et al.'' |title=Angiotensinogen gene polymorphisms M235T/T174M: no excess transmission to hypertensive Chinese |journal=[[Hypertension]] |volume=33 |issue=2 |pages=698–702 |year=1999 |month=February |pmid=10024331 |doi= |url=http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=10024331|accessdate=2009-06-08}}</ref><ref name="pmid10847327">{{cite journal |author=Luft FC |title=Molecular genetics of human hypertension |journal=[[Current Opinion in Nephrology and Hypertension]] |volume=9 |issue=3 |pages=259–66 |year=2000 |month=May |pmid=10847327 |doi= 10.1097/00041552-200005000-00009|url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1062-4821&volume=9&issue=3&spage=259|accessdate=2009-06-08}}</ref>

The best studied [[monogenic]] cause of hypertension is the [[Liddle syndrome]], a rare but clinically important disorder in which constitutive activation of the [[epithelial]] [[sodium channel]] predisposes to severe, treatment-resistant hypertension.<ref name="pmid7954808">{{cite journal |author=Shimkets RA, Warnock DG, Bositis CM, ''et al.'' |title=Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel |journal=[[Cell (journal)|Cell]] |volume=79 |issue=3 |pages=407–14 |year=1994 |month=November |pmid=7954808 |doi= 10.1016/0092-8674(94)90250-X|url=http://linkinghub.elsevier.com/retrieve/pii/0092-8674(94)90250-X|accessdate=2009-06-08}}</ref> Epithelial sodium channel activation resulting in inappropriate sodium retention at the
[[kidney|renal]] [[collecting duct]] level. Patients with the Liddle syndrome typically present with [[volume depletion|volume-dependent]], low [[renin]], and low [[aldosterone]], and [[hypertension]]. Screenings of general hypertensive populations indicate that the Liddle syndrome is rare and does not contribute substantially to the development of hypertension in the general population.<ref name="pmid9576123">{{cite journal |author=Melander O, Orho M, Fagerudd J, ''et al.'' |title=Mutations and variants of the epithelial sodium channel gene in Liddle's syndrome and primary hypertension |journal=[[Hypertension]] |volume=31 |issue=5 |pages=1118–24 |year=1998 |month=May |pmid=9576123 |doi= |url=http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=9576123|accessdate=2009-06-08}}</ref>

==Autonomic nervous system==
Also the [[autonomic nervous system]], plays a central role in maintaining the cardiovascular homeostasis via [[blood pressure|pressure]], [[Extracellular fluid|volume]], and [[Chemoreceptor#Heart_rate|chemoreceptor]] signals. Done by altering peripheral vasculature, and kidneys, causing increased [[cardiac output]], increased [[peripheral resistance|vascular resistance]], and [[Water retention (medicine)|fluid retention]]. Disorder of the system, as in case of [[sympathetic nervous system]] overactivity, increases blood pressure and contributes to the development and maintenance of hypertension.<ref name="pmid7922174">{{cite journal |author=Somers VK, Anderson EA, Mark AL |title=Sympathetic neural mechanisms in human hypertension |journal=[[Current Opinion in Nephrology and Hypertension]] |volume=2 |issue=1 |pages=96–105 |year=1993 |month=January |pmid=7922174 |doi= 10.1097/00041552-199301000-00015|url= }}</ref><ref name="pmid18700548">{{cite journal |author=Takahashi H |title=[Sympathetic hyperactivity in hypertension] |language=Japanese |journal=[[Nippon Rinsho. Japanese Journal of Clinical Medicine]] |volume=66 |issue=8 |pages=1495–502 |year=2008 |month=August |pmid=18700548 |doi= |url= }}</ref><ref name="pmid10921528">{{cite journal |author=Esler M |title=The sympathetic system and hypertension |journal=[[American Journal of Hypertension]] |volume=13 |issue=6 Pt 2 |pages=99S–105S |year=2000 |month=June |pmid=10921528 |doi= 10.1016/S0895-7061(00)00225-9|url= }}</ref><ref name="pmid9120673">{{cite journal |author=Mark AL |title=The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure |journal=[[Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension]] |volume=14 |issue=5 |pages=S159–65 |year=1996 |month=December |pmid=9120673 |doi= |url= }}</ref> In addition, [[autonomic nervous system|autonomic]] imbalance (i.e. increased [[sympathetic nervous system|sympathetic]] tone accompanied by reduced [[parasympathetic nervous system|parasympathetic]] tone) has been associated with many [[metabolic]] and [[hemodynamic]] abnormalities that result in increased [[cardiovascular]] [[morbidity]] and [[Death|mortality]].<ref name="pmid10921528"/><ref name="pmid10921530">{{cite journal |author=Brook RD, Julius S |title=Autonomic imbalance, hypertension, and cardiovascular risk |journal=[[American Journal of Hypertension]] |volume=13 |issue=6 Pt 2 |pages=112S–122S |year=2000 |month=June |pmid=10921530 |doi= 10.1016/S0895-7061(00)00228-4|url= }}</ref>

The mechanisms of increased sympathetic nervous system activity in hypertension are complex and involve alterations in [[baroreflex]] and [[Peripheral chemoreceptors|chemoreflex]] pathways at both peripheral and central levels. [[baroreceptors|Arterial baroreceptors]] are reset to a higher pressure in hypertensive patients, and this peripheral resetting reverts to normal when arterial pressure is normalized.<ref name="pmid">{{cite journal |author=Chapleau MW, Hajduczok G, Abboud FM |title=Mechanisms of resetting of arterial baroreceptors: an overview |journal=[[The American Journal of the Medical Sciences]] |volume=295 |issue=4 |pages=327–34 |year=1988 |month=April |pmid= 2834951|doi= 10.1097/00000441-198804000-00019|url= }}</ref><ref name="pmid6883646">{{cite journal |author=Guo GB, Thames MD, Abboud FM |title=Arterial baroreflexes in renal hypertensive rabbits. Selectivity and redundancy of baroreceptor influence on heart rate, vascular resistance, and lumbar sympathetic nerve activity |journal=[[Circulation Research]] |volume=53 |issue=2 |pages=223–34 |year=1983 |month=August |pmid=6883646 |doi= |url=http://circres.ahajournals.org/cgi/pmidlookup?view=long&pmid=6883646|accessdate=2009-06-08}}</ref><ref name="pmid2117025">{{cite journal |author=Xie PL, Chapleau MW, McDowell TS, Hajduczok G, Abboud FM |title=Mechanism of decreased baroreceptor activity in chronic hypertensive rabbits. Role of endogenous prostanoids |journal=[[The Journal of Clinical Investigation]] |volume=86 |issue=2 |pages=625–30 |year=1990 |month=August |pmid=2117025 |pmc=296770 |doi=10.1172/JCI114754}}</ref> Furthermore, there is [[central nervous system|central]] resetting of the [[Aortic body|aortic baroreflex]] in hypertensive patients, resulting in suppression of sympathetic inhibition after activation of aortic baroreceptor nerves. This baroreflex resetting seems to be mediated, at least partly, by a central action of [[angiotensin II]].<ref name="pmid11411750">{{cite journal |author=Lohmeier TE |title=The sympathetic nervous system and long-term blood pressure regulation |journal=[[American Journal of Hypertension]] |volume=14 |issue=6 Pt 2 |pages=147S–154S |year=2001 |month=June |pmid=11411750 |doi= 10.1016/S0895-7061(01)02082-9|url= }}</ref><ref name="pmid6720985">{{cite journal |author=Guo GB, Abboud FM |title=Impaired central mediation of the arterial baroreflex in chronic renal hypertension |journal=[[The American Journal of Physiology]] |volume=246 |issue=5 Pt 2 |pages=H720–7 |year=1984 |month=May |pmid=6720985 |doi= |url=http://ajpheart.physiology.org/cgi/pmidlookup?view=long&pmid=6720985|accessdate=2009-06-08}}</ref><ref name="pmid4359754">{{cite journal |author=Abboud FM |title=Effects of sodium, angiotensin, and steroids on vascular reactivity in man |journal=[[Federation Proceedings]] |volume=33 |issue=2 |pages=143–9 |year=1974 |month=February |pmid=4359754 |doi= |url= }}</ref> Additional small-molecule [[chemical mediator|mediators]] that suppress baroreceptor activity and contribute to exaggerated sympathetic drive in hypertension include [[reactive oxygen species]] and [[endothelin]].<ref name="pmid8831504">{{cite journal |author=Li Z, Mao HZ, Abboud FM, Chapleau MW |title=Oxygen-derived free radicals contribute to baroreceptor dysfunction in atherosclerotic rabbits |journal=[[Circulation Research]] |volume=79 |issue=4 |pages=802–11 |year=1996 |month=October |doi= |url=http://circres.ahajournals.org/cgi/pmidlookup?view=long&pmid=8831504|accessdate=2009-06-08 |pmid= 8831504}}</ref><ref name="pmid1636777">{{cite journal |author=Chapleau MW, Hajduczok G, Abboud FM |title=Suppression of baroreceptor discharge by endothelin at high carotid sinus pressure |journal=[[The American Journal of Physiology]] |volume=263 |issue=1 Pt 2 |pages=R103–8 |year=1992 |month=July |pmid= 1636777|doi= |url=http://ajpregu.physiology.org/cgi/pmidlookup?view=reprint&pmid=1636777|accessdate=2009-06-08}}</ref> Some studies shown that hypertensive patients manifest greater [[vasoconstrictor]] responses to infused [[norepinephrine]] than [[normotensive]] controls.<ref name="pmid1873013">{{cite journal |author=Ziegler MG, Mills P, Dimsdale JE |title=Hypertensives' pressor response to norepinephrine. Analysis by infusion rate and plasma levels |journal=[[American Journal of Hypertension]] |volume=4 |issue=7 Pt 1 |pages=586–91 |year=1991 |month=July |pmid=1873013 |doi= |url= }}</ref> And that hypertensive patients do not show the normal response to increased circulating norepinephrine
levels which generally induces downregulation of [[noradrenergic receptor]], and its believed that this abnormal response is [[Genetics|genetically]] [[inheritance|inherited]].<ref name="pmid3520094">{{cite journal |author=Bianchetti MG, Beretta-Piccoli C, Weidmann P, Ferrier C |title=Blood pressure control in normotensive members of hypertensive families |journal=[[Kidney International (journal)|Kidney International]] |volume=29 |issue=4 |pages=882–8 |year=1986 |month=April |pmid=3520094 |doi= 10.1038/ki.1986.81|url= }}</ref>

Exposure to [[stress (biological)|stress]] increases sympathetic outflow, and repeated stress-induced vasoconstriction may result in [[hypertrophy|vascular hypertrophy]], leading to progressive increases in [[peripheral resistance]] and blood pressure.<ref name="pmid14597461">{{cite journal |author=Oparil S, Zaman MA, Calhoun DA |title=Pathogenesis of hypertension |journal=[[Annals of Internal Medicine]] |volume=139 |issue=9 |pages=761–76 |year=2003 |month=November |pmid=14597461 |doi= |url= }}</ref> This could partly explain the greater incidence of hypertension in [[lower socioeconomic groups]], since they must endure greater levels of stress associated with daily living. Persons with a family history of hypertension manifest augmented vasoconstrictor and sympathetic responses to laboratory stressors, such as [[cold pressor testing]] and [[Mind|mental]] stress, that may predispose them to hypertension. This is particularly true of young African Americans. Exaggerated stress responses may contribute to the increased incidence of hypertension in this group.<ref name="pmid8244512">{{cite journal |author=Calhoun DA, Mutinga ML, Collins AS, Wyss JM, Oparil S |title=Normotensive blacks have heightened sympathetic response to cold pressor test |journal=[[Hypertension]] |volume=22 |issue=6 |pages=801–5 |year=1993 |month=December |pmid=8244512 |doi= |url=http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=8244512|accessdate=2009-06-09}}</ref>

==Renin-angiotensin-aldosterone system==
Another system maintaining the [[Extracellular fluid|extracellular fluid volume]], [[Total peripheral resistance|peripheral resistance]] and  that if disturbed may lead to hypertension, is the [[renin-angiotensin-aldosterone system]]. [[Renin]] is a circulating [[enzyme]] that participates in maintaining [[extracellular]] volume, and arterial [[vasoconstriction]], Thus it contributing to regulation of the [[blood pressure]], it performs this function through breaking down ([[hydrolyzes]]) [[angiotensinogen]] secreted from the liver into the peptide [[angiotensin I]], Angiotensin I is further cleaved by an enzyme that is located primarily but not exclusively in the [[pulmonary circulation]] bound to [[endothelium]], that enzyme is [[angiotensin converting enzyme]] (ACE) producing [[angiotensin II]], the most vasoactive peptide.<ref>{{cite journal |author=Fujino T, Nakagawa N, Yuhki K, ''et al.'' |title=Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP |journal=J. Clin. Invest. |volume=114 |issue=6 |pages=805–12 |year=2004 |month=September |pmid=15372104 |pmc=516260 |doi=10.1172/JCI21382 |url=http://www.jci.org/cgi/content/full/114/6/805?ijkey=e3335f0a9a7b40386d49e7172910ea6345c9342a}}</ref><ref>Brenner & Rector's The Kidney, 7th ed., Saunders, 2004. pp.2118-2119.[http://home.mdconsult.com/das/book/56203699-6/view/1201?sid=460067115 Full Text with MDConsult subscription]</ref> Angiotensin II is a potent constrictor of all blood vessels. It acts on the musculature of arteries and thereby raises the peripheral resistance, and so elevates blood pressure. Angiotensin II also acts on the adrenal glands too and releases [[Aldosterone]], which stimulates the epithelial cells of the kidneys to increase re-absorption of salt and water leading to raised blood volume and raised blood pressure. So elevation of [[renin]] level in the blood, which is normally in adult human is 1.98-24.6&nbsp;ng/L in the upright position.<ref>Hamilton Regional Laboratory Medicine Program - Laboratory Reference Centre Manual. [http://142.238.64.246/detail.asp?RecNumber=723&TestFind=renin&SortBy=Name&ViewAlpha=&ParNum= Renin Direct]</ref> will lead to hypertension.<ref name="pmid14597461"/><ref name="pmid10354958">{{cite journal |author=McConnaughey MM, McConnaughey JS, Ingenito AJ |title=Practical considerations of the pharmacology of angiotensin receptor blockers |journal=[[Journal of Clinical Pharmacology]] |volume=39 |issue=6 |pages=547–59 |year=1999 |month=June |pmid=10354958 |doi= 10.1177/00912709922008155|url=http://jcp.sagepub.com/cgi/pmidlookup?view=long&pmid=10354958|accessdate=2009-06-09}}</ref>

Recent studies claim that obesity is a risk factor for hypertension because of activation of the [[renin-angiotensin system]] (RAS) in [[adipose tissue]],<ref name="pmid17903324">{{cite journal |author=Segura J, Ruilope LM |title=Obesity, essential hypertension and renin-angiotensin system |journal=[[Public Health Nutrition]] |volume=10 |issue=10A |pages=1151–5 |year=2007 |month=October |pmid=17903324 |doi=10.1017/S136898000700064X |url=http://journals.cambridge.org/abstract_S136898000700064X|accessdate=2009-06-02}}</ref><ref name="pmid19348224">{{cite journal |author=Hasegawa H, Komuro I |title=[The progress of the study of RAAS] |language=Japanese |journal=[[Nippon Rinsho. Japanese Journal of Clinical Medicine]] |volume=67 |issue=4 |pages=655–61 |year=2009 |month=April |pmid=19348224 |doi= |url= }}</ref> and also linked [[renin-angiotensin system]] with [[insulin resistance]], and claims that anyone can cause the other.<ref name="pmid19348235">{{cite journal |author=Saitoh S |title=[Insulin resistance and renin-angiotensin-aldosterone system] |language=Japanese |journal=[[Nippon Rinsho. Japanese Journal of Clinical Medicine]] |volume=67 |issue=4 |pages=729–34 |year=2009 |month=April |pmid=19348235 |doi= |url= }}</ref> Local production of [[angiotensin II]] in various tissues, including the [[blood vessels]], [[heart]], [[adrenals]], and [[brain]], is controlled by [[Angiotensin-converting enzyme|ACE]] and other [[enzyme]]s, including the [[serine protease]] [[chymase]]. The activity of local renin–angiotensin systems and alternative pathways of angiotensin II formation may make an important contribution to remodeling of resistance [[blood vessel|vessel]]s and the development of target organ damage (i.e. [[left ventricular hypertrophy]], [[congestive heart failure]], [[atherosclerosis]], [[stroke]], [[end-stage renal disease]], [[myocardial infarction]], and [[arterial aneurysm]]) in hypertensive persons.<ref name="pmid10354958"/>

==Endothelial dysfunction==
The [[endothelium]] of blood vessels produces an extensive range of substances that influence [[blood flow]] and, in turn, is affected by changes in the blood and the pressure of blood flow. For example, local [[nitric oxide]] and [[endothelin]], which are secreted by the endothelium, are the major regulators of vascular tone and blood pressure. In patients with essential hypertension, the balance between the [[vasodilators]] and the [[vasoconstrictors]] is upset, which leads to changes in the endothelium and sets up a “[[vicious cycle]]” that contributes to the maintenance of high blood pressure. In patients with hypertension, [[endothelial activation]] and damage also lead to changes in [[Vascular resistance|vascular tone]], vascular reactivity, and [[coagulation]] and [[Fibrinolysis|fibrinolytic pathways]]. Alterations in endothelial function are a reliable indicator of target organ damage and atherosclerotic disease, as well as prognosis.<ref name="isbn1-4051-3061-X">{{cite book |author=O'Brien, Eoin; Beevers, D. G.; Lip, Gregory Y. H. |authorlink= |editor= |others= |title=ABC of hypertension |edition= |language= |publisher=BMJ Books |location=London |year=2007 |origyear= |pages= |quote= |isbn=1-4051-3061-X |oclc= |doi= |url= |accessdate=}}</ref>

Multiple evidences suggest that [[oxidant stress]] alters many functions of the [[endothelium]], including modulation of [[vasomotor tone]]. Inactivation of [[nitric oxide]] ([[nitric oxide|NO]]) by [[superoxide]] and other [[reactive oxygen species]] ([[reactive oxygen species|ROS]]) seems to occur in conditions such as [[hypertension]].<ref name="pmid1658794">{{cite journal |author=Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M |title=Does superoxide underlie the pathogenesis of hypertension? |journal=[[Proceedings of the National Academy of Sciences of the United States of America]] |volume=88 |issue=22 |pages=10045–8 |year=1991 |month=November |pmid=1658794 |pmc=52864 |doi= 10.1073/pnas.88.22.10045|url= }}</ref><ref name="pmid9024144">{{cite journal |author=Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG |title=Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension |journal=[[Circulation (journal)|Circulation]] |volume=95 |issue=3 |pages=588–93 |year=1997 |month=February |pmid=9024144 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=9024144|accessdate=2009-06-09}}</ref><ref name="pmid11073878">{{cite journal |author=Cai H, Harrison DG |title=Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress |journal=[[Circulation Research]] |volume=87 |issue=10 |pages=840–4 |year=2000 |month=November |pmid=11073878 |doi= |url=http://circres.ahajournals.org/cgi/pmidlookup?view=long&pmid=11073878|accessdate=2009-06-09}}</ref> Normally [[nitric oxide]] is an important regulator and mediator of numerous processes in the [[immune systems|nervous]], [[immune systems|immune]] and [[cardiovascular system]]s, including [[smooth muscle]] relaxation thus resulting in [[vasodilation]] of the [[artery]] and increasing [[blood flow]], suppressor of migration and proliferation of vascular smooth-muscle cells.<ref name="pmid14597461"/> It has been suggested that [[angiotensin II]] enhances formation of the oxidant superoxide at concentrations that affect blood pressure minimally.<ref name="pmid8978321">{{cite journal |author=Fukui T, Ishizaka N, Rajagopalan S, ''et al.'' |title=p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats |journal=[[Circulation Research]] |volume=80 |issue=1 |pages=45–51 |year=1997 |month=January |pmid=8978321 |doi= |url=http://circres.ahajournals.org/cgi/pmidlookup?view=long&pmid=8978321|accessdate=2009-06-09}}</ref>

[[Endothelin]] is a potent vasoactive peptide produced by endothelial cells that has both [[vasoconstrictor]] and vasodilator properties. Circulating endothelin levels are increased in some hypertensive patients,<ref name="pmid12839265">{{cite journal |author=Touyz RM, Schiffrin EL |title=Role of endothelin in human hypertension |journal=[[Canadian Journal of Physiology and Pharmacology]] |volume=81 |issue=6 |pages=533–41 |year=2003 |month=June |pmid=12839265 |doi=10.1139/y03-009 |url=http://article.pubs.nrc-cnrc.gc.ca/ppv/RPViewDoc?issn=0008-4212&volume=81&issue=6&startPage=533|accessdate=2009-06-09}}</ref><ref name="pmid12839265"/><ref name="pmid17641406">{{cite journal |author=Shreenivas S, Oparil S |title=The role of endothelin-1 in human hypertension |journal=[[Clinical Hemorheology and Microcirculation]] |volume=37 |issue=1–2 |pages=157–78 |year=2007 |pmid=17641406 |doi= |url=http://iospress.metapress.com/openurl.asp?genre=article&issn=1386-0291&volume=37&issue=1&spage=157|accessdate=2009-06-09}}</ref> particularly [[African Americans]] and persons with hypertension.<ref name="pmid12839265"/><ref name="pmid8843893">{{cite journal |author=Ergul S, Parish DC, Puett D, Ergul A |title=Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension |journal=[[Hypertension]] |volume=28 |issue=4 |pages=652–5 |year=1996 |month=October |pmid=8843893 |doi= |url=http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=8843893|accessdate=2009-06-09}}</ref><ref name="pmid11763297">{{cite journal |author=Grubbs AL, Ergul A |title=A review of endothelin and hypertension in African-American individuals |journal=[[Ethnicity & Disease]] |volume=11 |issue=4 |pages=741–8 |year=2001 |pmid=11763297 |doi= |url= }}</ref><ref name="pmid15148269">{{cite journal |author=Campia U, Cardillo C, Panza JA |title=Ethnic differences in the vasoconstrictor activity of endogenous endothelin-1 in hypertensive patients |journal=[[Circulation (journal)|Circulation]] |volume=109 |issue=25 |pages=3191–5 |year=2004 |month=June |pmid=15148269 |doi=10.1161/01.CIR.0000130590.24107.D3 |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=15148269|accessdate=2009-06-09}}</ref>

==References==
{{reflist|2}}

{{Vascular diseases}}

{{DEFAULTSORT:Pathophysiology Of Hypertension}}
[[Category:Hypertension| ]]
[[Category:Pathophysiology|Hypertension]]
[[Category:Cardiology]]
[[Category:Cardiovascular diseases]]
[[Category:Medical conditions related to obesity]]